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Abstract: Background and Aims: The association of fatty acids with coronary heart disease (CHD)
has been examined, mainly through dietary measurements, and has generated inconsistent results
due to measurement error. Large observational studies and randomized controlled trials have
shown that plasma phospholipid fatty acids (PL-FA), especially those less likely to be endogenously
synthesized, are good biomarkers of dietary fatty acids. Thus, PL-FA profiles may better predict
CHD risk with less measurement error. Methods: We performed a matched case-control study
of 2428 postmenopausal women nested in the Women’s Health Initiative Observational Study.
Plasma PL-FA were measured using gas chromatography and expressed as molar percentage
(mol %). Multivariable conditional logistic regression was used to calculate odds ratios (95% CIs)
for CHD associated with 1 moL % change in PL-FA. Results: Higher plasma PL long-chain saturated
fatty acids (SFA) were associated with increased CHD risk, while higher n-3 polyunsaturated fatty
acids (PUFA) were associated with decreased risk. No significant associations were observed for
very-long-chain SFA, monounsaturated fatty acids (MUFA), PUFA n-6 or trans fatty acids (TFA).
Substituting 1 moL % PUFA n-6 or TFA with an equivalent proportion of PUFA n-3 were associated
with lower CHD risk. Conclusions: Higher plasma PL long-chain SFA and lower PUFA n-3 were
associated with increased CHD risk. A change in diet by limiting foods that are associated with
plasma PL long-chain SFA and TFA while enhancing foods high in PUFA n-3 may be beneficial in
CHD among postmenopausal women.
Nutrients 2019, 11, 1672; doi:10.3390/nu11071672 www.mdpi.com/journal/nutrients
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1. Introduction
The relationship between fat intake and heart disease is not entirely clear, particularly among
postmenopausal women with relatively low fat consumption [1,2]. Some meta-analyses of observational
studies and randomized controlled trials found no association between saturated fatty acids (SFA)
and risk of coronary heart disease (CHD) [3,4]. However, these studies lack a consideration of the
nutrient substitution framework, under which significant associations have been observed [5–7].
Dietary intervention trials have demonstrated that SFA elevate total cholesterol and low-density
lipoprotein cholesterol (LDL-C), and substituting SFA with polyunsaturated fatty acids (PUFA) is
associated with lower CHD risk [8,9]. Based on the above evidence, several professional organizations
have recommended diets limiting SFA and increasing PUFA n-3 [10,11].
Until recently, all SFA were viewed as unhealthy as refined carbohydrates when considering
their impact on increasing LDL-C and total cholesterol. Although not all SFA have the same
cholesterol-raising effect, no recommendations have been made for specific SFA due to insufficient
evidence. Evidence supporting the associations of monounsaturated fatty acids (MUFA) and PUFA
n-6 with CHD risk is also less definitive [4,12]. A recent meta-analysis of prospective observational
studies and randomized trials concluded that there was no significant association of dietary MUFA and
PUFA n-6 with CHD risk, but a higher CHD risk of trans fatty acids (TFA) (pooled RR (95% Cis): 1.16
(1.06–1.27)) and a lower CHD risk of long-chain PUFA n-3 (0.87 (0.78–0.97)) [4]. Several investigators
have questioned the interpretation of these results [9,13]. One major concern was that the macronutrient
for replacement, which could have had an independent association with CHD outcome, was not
identified or accounted for [9,13]. An additional concern was that the dietary assessment methods in
these reports were via self-report instruments, which is valid when ranking individuals according to
the intake levels, but contributes substantial systematic measurement error when the absolute intake
levels are of interest.
To address these concerns, the Multi-Ethnic Study of Atherosclerosis [12,14] and the Women’s
Health Initiative Observational Study (WHI-OS) [15] have measured plasma phospholipid fatty acids
(PL-FA) as indicators of medium-term dietary FA intake [16,17], and have shown associations between
PL-FA and CHD risk. Specifically, one interquartile range increase in PL long-chain PUFA n-3 or
SFA 15:0 were associated with a lower CHD risk (HR (95%CIs), 0.40 (0.23–0.69) and 0.76 (0.61–0.93),
respectively) [12,14]; 1 moL % increase in PL SFA was associated with a 20% higher CHD risk (95% CIs
1.08–1.32); and 1 moL % increase in PL PUFA n-3 was associated with a 11% lower CHD risk (95% CIs
0.83–0.97) [15]. While plasma PL-FA offer an objective biomarker of dietary FA that could potentially
reduce the measurement error from questionnaires or diet recalls, plasma PL-FA reflect both dietary
intake and endogenous synthesis. Therefore, caution is needed when interpreting the association with
disease outcome.
Large observational studies and dietary intervention trials have demonstrated that PL-FA profiles
are good biomarkers of dietary fat, especially for those FA with limited in vivo synthesis—PUFA n-3,
n-6, and TFA [16,18]. In addition, randomized trials have shown that substituting dietary PUFA n-6
with PUFA n-3 at 10% of total energy led to a 2–3% plasma substitution [19]. Thus, the substitution of
plasma PL-FA by changes in dietary fat types has a potential for evaluating the association of specific
dietary FA with CHD risk, with less measurement error. However, the substitution of plasma PL-FA
has not been examined so far, and we are still lack evidence from postmenopausal women.
Based upon the previously reported associations between plasma PL-FA and CHD, we sought
to examine the following: (1) the association of plasma PL-FA levels, specifically long-chain and
very-long-chain plasma PL SFA, with CHD risk; (2) the effect of substituting plasma PUFA n-6 and
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TFA with PUFA n-3 on CHD risk; and (3) potential food groups that are correlated with plasma PL-FA,
using data from the WHI study.
2. Materials and Methods
2.1. Study Population
The WHI-OS is a prospective cohort study that enrolled 93,676 postmenopausal women between
the ages of 50 and 79 years in the United States from 1994 to 1998. It is designed to assess the biological,
lifestyle, and genetic factors for CHD and other major health events among postmenopausal women.
A detailed description of the WHI study design has been published elsewhere [20,21].
A matched case-control design was used for the current study. All CHD cases, including hospitalized
myocardial infarction (MI), definite silent MI, and coronary death, were confirmed based on medical
records and death certificates. The cases included in the current study were a random sample of all
CHD cases identified based on the September 2005 database [22]. A total of 2468 cases were initially
selected and those who met the following criteria were excluded: (1) lack of sufficient baseline plasma
sample (N = 28) (2) missing baseline dietary measurement (N = 126), and (3) self-reported baseline CVD,
which includes angina, MI, coronary artery bypass graft (CABG) surgery, percutaneous transluminal
coronary angioplasty (PTCA), carotid artery disease, congestive heart failure, stroke or peripheral
vascular disease (N = 765). Potential controls were women from the entire WHI-OS who did not develop
CVD during the follow-up (a mean of 4.5 years) and were excluded if meeting the same exclusion criteria
as the cases. Cases and controls were matched on age at screening, enrollment date, race/ethnicity
(White, Black, Hispanic, other), and hysterectomy status. The sample size for PL-FA assays included
1224 matched case-control pairs and 10% blind duplicates for quality control. We additionally excluded
20 participants due to the lack of plasma PL-FA profile results (N = 11) or missing matched pairs
(N = 9), and came up with a final sample size of 1214 matched pairs. A separate approval for using
de-identified samples and data for this study was obtained from the Tufts University/Tufts Medical
Center Institutional Review Board [15].
2.2. Plasma PL-FA Profiles
Blood samples were collected at baseline and a minimum of 12 h fasting before blood draw was
required. All blood samples were maintained at 4 ◦C for up to an hour until plasma was separated from
cells, frozen at −20 ◦C, and then sent to the central repository stored at −80 ◦C. Plasma PL-FA profiles
were measured by an established gas chromatography method [23] at Tufts University. Peaks of interest
were identified by comparison with authentic FA standards (National Institute of Health Fatty Acid
Standards A, B, and C, Nu-Check-Prep, Elysian, MN, USA), and expressed as molar percentage (moL %)
proportions of FA relative to the internal standard (heptadecanoic acid). Internal and external quality
controls were performed to guarantee the validity of the measurements, and detailed information has
been published previously [15]. A total of 28 individual plasma PL-FA were measured. We classified
these FA into groups based on the number of double bonds—specifically SFA, MUFA, PUFA n-3,
PUFA n-6, and TFA. We further classified FA by the length of FA chains: long-chain FA are those
with 12–19 carbons and very-long-chain FA are those with 20 or more carbons. Table 1 shows the
lipid names, common names, categories, and mean (SD) levels of individual plasma PL-FA that were
included in this study.
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Table 1. The lipid names, common names, categories, and mean (SD) levels (moL %) of plasma
phospholipid fatty acid profiles measured in the matched case-control study of the Women’s Health
Initiative (1994–2005) (N = 2428).
Lipid Names a Common Names Category Mean (SD) Levels (moL %)
SFA 46.09 (1.29)
12:0 Lauric acid Long-chain 0.07 (0.04)
14:0 Myristic acid Long-chain 0.69 (0.21)
15:0 Pentadecylic acid Long-chain 0.23 (0.05)
16:0 Palmitic acid Long-chain 30.57 (2.02)
18:0 Stearic acid Long-chain 13.19 (1.42)
20:0 Arachidic acid Very-long-chain 0.24 (0.07)
22:0 Behenic acid Very-long-chain 0.64 (0.23)
24:0 Lignoceric acid Very-long-chain 0.46 (0.18)
MUFA 11.77 (1.64)
14:1 5-myristoleic acid Long-chain 0.12 (0.10)
16:1 n-9 7-palmitoleic acid Long-chain 0.84 (0.32)
16:1 n-7 cis-9-palmitoleic acid Long-chain 0.12 (0.05)
18:1 n-9 Oleic acid Long chain 1.37 (0.28)
18:1 n-7 Vaccenic acid Long-chain 8.48 (1.37)
20:1 n-9 cis-gondoic acid Very-long-chain 0.08 (0.03)
24:1 n-9 Nervonic acid Very-long-chain 0.77 (0.30)
PUFA 41.60 (2.06)
PUFA n-6 36.31 (2.46)
18:2 n-6 Linoleic acid (LA) Long-chain 20.79 (3.00)
18:3 n-6 γ-linoleic acid Long-chain 0.10 (0.05)
20:2 n-6 Eicosadienoic acid Very-long-chain 0.40 (0.16)
20:3 n-6 Eicosatrienoic acid Very-long-chain 3.32 (0.79)
20:4 n-6 Arachidonic acid (AA) Very-long-chain 10.93 (2.07)
22:4 n-6 Docosatetraenoic acid Very-long-chain 0.42 (0.11)
22:5 n-6 4,7,10,13,16-Docosapentaenoic acid Very-long-chain 0.35 (0.13)
PUFA n-3 5.14 (1.58)
18:3 n-3 α-linolenic acid (ALA) Long-chain 0.21 (0.08)
20:5 n-3 Eicosapentaenoic acid (EPA) Very-long-chain 0.81 (0.51)
22:5 n-3 7,10,13,16,19-Docosapentaenoic acid(DPA) Very-long-chain 0.83 (0.19)
22:6 n-3 Docosahexaenoic acid (DHA) Very-long-chain 3.29 (1.13)
TFA 0.69 (0.34)
18:1t All 18:1 trans Long-chain 0.54 (0.30)
18:2t All 18:2 trans Long-chain 0.14 (0.06)
a Lipid names are presented in the form of C:D, where C is the number of carbon atoms and D is the number of
double bonds in the fatty acid. Abbreviations: MUFA (mono-unsaturated fatty acids), PUFA (polyunsaturated fatty
acids), SD (standard deviation), SFA (saturated fatty acids), TFA (trans fatty acids).
2.3. Covariates and Dietary Data
Standard questionnaires following the same protocol were utilized throughout the study to
collect information related to socio-demographics, lifestyle factors, and CHD risk factors [20].
We initially considered the following variables as potential confounders: (1) socio-demographic
variables (including age, U.S. region, race/ethnicity, education, and income); (2) lifestyle factors
such as recreational physical activity, body mass index (BMI), waist circumference, waist-to-hip ratio,
and smoking; and (3) CHD risk factors (family history of MI/diabetes/stroke, anticoagulant/anti-diabetic/
lipid lowering medication use, postmenopausal hormone use, and self-reported hypertension/diabetes/
hypercholesterolemia/hysterectomy status at baseline).
Information on nutrient intake and food consumption was assessed by food frequency questionnaire
at baseline [20]. Potential dietary confounders included alcohol intake (g/day), percent calories from
protein/carbohydrates, and total energy intake (kcal/day) [24]. Foods high in fats or that have the
potential to influence fat metabolism were assessed for further correlation analysis with plasma PL-FA.
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For this analysis, we considered the following nine food groups: fish, dairy products, butter, margarine,
olive/canola oil, other vegetable oils, red meat, alcohol, and carbohydrates [25–28].
Age and BMI were treated as continuous variables. Physical activity, measured by recreational
physical activity score (MET-h/week) based on a series of questions related to exercise intensity levels [29],
was treated as continuous or categorical dichotomized at median. Education was categorized as ≤high
school, some college, or postgraduate. Income was categorized as <$20,000, $20,000–74,999, or≥$75,000
per year. Smoking was categorized as current, past, or never smoker. Family history was defined as
first-degree relatives having MI, diabetes, or stroke. Postmenopausal hormone use was categorized into
current estrogen + progesterone, current estrogen alone, past users, or never used. Hypertension was
defined as self-reported hypertension/taking antihypertensive medication, or systolic blood pressure
≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg. Baseline diabetes and hypercholesterolemia
were defined as taking anti-diabetic or cholesterol-lowering medications, respectively.
2.4. Statistical Analysis
We initially examined the baseline distribution of socio-demographics, lifestyle factors, CHD risk
factors, and dietary factors by CHD status, as well as by five subtypes of plasma PL-FA in
tertiles (Appendix A). Descriptive statistics such as median, mean, standard deviation, frequency,
and proportion were used to summarize the aforementioned variables. Depending on the distribution
of the variables, we used the paired t-test, Wilcoxon signed rank test, or McNemar test for the
comparison between cases and controls.
We employed multivariable conditional logistic regression models to estimate odds ratios (ORs)
and corresponding 95% confidence intervals (CIs) for CHD risk in association with a 1 moL % increase
in plasma PL-FA. The covariates in the multivariable model were selected based on a hypothesized
causal diagram (Appendix B) to adjust for potential confounding, and a backward selection method
was used to generate a parsimonious model with the best model fit [30]. The final multivariable model
adjusted for matching factors (age, race/ethnicity, enrollment date, and hysterectomy status), income,
physical activity, smoking, family history of MI/diabetes, postmenopausal hormone use, self-reported
hypertension/diabetes, percent calories from protein/carbohydrates, and total energy intake. We have
performed model diagnosis and examined model assumptions. No outlier was observed and all model
assumptions held.
Linoleic, α-linolenic, and trans FA cannot be synthesized in vivo. In addition, the elongase and
desaturase enzymes in human livers have low activity when regulating the synthesis of long-chain
PUFA from their precursors [31]. Therefore, plasma PL PUFA n-3, n-6, and TFA are good biomarkers
of corresponding dietary FA, and substitutions of dietary FA can be estimated by plasma substitutions.
To estimate the theoretical effect of substituting 1 moL % of plasma PL PUFA n-6 with the same
proportion of PUFA n-3, we left out PUFA n-6 in the multivariable model. The relation can be expressed
as follows:
logit (CHD risk) = β1 * PL PUFA n-3 + β2 * PL SFA + β3 * PL MUFA + β4 * PL TFA (1)
where β1 to β4 are regression coefficients. The total of all PL-FA is 100 moL %, so that the coefficient
β1 can be interpreted as the effect of substituting 1 moL % of PUFA n-6 with the same proportion of
PUFA n-3 while holding other FA constant [24]. This substitution model was similarly applied to TFA
substitution analysis.
To further examine potential food sources that related to plasma PL-FA levels, we calculated
Spearman’s rank correlation coefficients between plasma PL-FA levels and the consumption of nine
selected food groups. Considering the cases might have altered metabolic status, thus not representing
the overall population, the correlation coefficients were calculated among controls only, adjusting for
matching factors and the aforementioned non-dietary confounders.
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Multiple imputation (five times) by chained equations [32] was used to impute missing values on
the following covariates: income (N = 118), physical activity (N = 28), smoking (N = 28), family history
(N = 209, among which 119 were missing MI and 122 were missing diabetes), and self-reported
hypertension (N = 47) and diabetes (N = 2).
We conducted the following sensitivity analyses to assess the robustness of findings: (1) comparing
the association analysis results from different regression models; (2) examining the association
between plasma PL-FA groups and CHD additionally adjusting for anthropometric measures
(BMI, waist circumference, waist-to-hip ratio) and chronic weight cycling (three-year BMI change);
(3) performing substitution analysis stratified by physical activity levels; and (4) performing the
association and substitution analyses among participants with complete information (N = 2181).
All analyses were performed using Statistics Analysis Systems software package (version 9.4;
SAS Institute, Inc., Cary, NC, USA).
3. Results
The characteristics of the cases and controls can be found in Table 2. The mean (SD) age was 67.8
(6.8) years, and the median time from baseline plasma PL-FA measures to CHD event among cases
was 4.5 years. Compared with controls, cases had significantly lower education and income levels,
higher BMI (26.9 vs. 25.9 kg/m2) and lower physical activity level (8.3 vs. 10.8 MET-h/week). More cases
were smokers, had hypertension or diabetes, or reported a family history of MI and medication use,
while fewer were currently using postmenopausal hormones.
Table 2. Baseline characteristics by cases and controls in the Women’s Health Initiative study (1994–2005)
(N = 2428).
Variables Overall
CHD Status
Controls (N = 1214) Cases (N = 1214) p-Values a
Socio-demographics
Age, years b 67.8 (6.8) 67.8 (6.8) 67.8 (6.8) Matched
Race/ethnicity, n (%) Matched
Black 136 (6) 68 (6) 68 (6)
Hispanic 32 (1) 16 (1) 16 (1)
White 2172 (90) 1086 (90) 1086 (90)
Other 88 (4) 44 (4) 44 (4)
Region, n (%) 0.40
Northeast 610 (25) 303 (25) 307 (25)
South 579 (24) 299 (25) 280 (23)
Midwest 547 (23) 264 (22) 283 (23)
West 692 (29) 348 (29) 344 (28)
Education, n (%) <0.01
≤High school 845 (35) 380 (31) 465 (38)
Some college and college graduate 907 (37) 471 (39) 435 (36)
Postgraduate 676 (28) 363 (30) 314 (26)
Income, n (%) <0.01
<$20,000 448 (18) 193 (16) 255 (21)
$20,000–$74,999 1541 (64) 776 (64) 765 (63)
≥$75,000 439 (18) 245 (20) 194 (16)
Lifestyle factors
Physical activity, MET-h/week c 9.5 (16.1) 10.8 (17.3) 8.3 (15.4) <0.01
BMI, Kg/m2 c 26.4 (6.8) 25.9 (6.4) 26.9 (7.4) <0.01
Waist circumference, cm c 84.2 (13.6) 83.0 (12.3) 86.5 (14.4) <0.01
Waist-to-hip ratio c 0.8 (0.1) 0.8 (0.1) 0.8 (0.1) <0.01
Smoking, n (%) <0.01
Never-smoker 1232 (51) 650 (54) 582 (48)
Past smoker 1033 (43) 501 (41) 532 (44)
Current smoker 163 (7) 63 (5) 100 (8)
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Table 2. Cont.
CHD risk factors
Family history, n (% yes)
Myocardial infarction 1383 (57) 647 (53) 736 (61) <0.01
Diabetes 829 (34) 441 (36) 388 (32) 0.03
Stroke 986 (41) 473 (39) 513 (42) 0.11
Medication use, n (%) d 364 (15) 123 (10) 241 (20) <0.01
Hormone usage, n (%) <0.01
Current Estrogen + Progesterone 355 (15) 205 (17) 150 (12)
Current Estrogen alone 555 (23) 295 (24) 260 (21)
Past Users 375 (15) 175 (14) 200 (17)
Never Used 1143 (47) 539 (44) 604 (50)
Hypertension, n (%) <0.01
Never hypertensive 1409 (58) 824 (68) 585 (48)
Untreated hypertensive 237 (10) 96 (8) 141 (12)
Treated hypertensive 782 (32) 294 (24) 488 (40)
Diabetes, n (% yes) 197 (8) 46 (4) 151 (12) <0.01
Hypercholesterolemia, n (% yes) 380 (16) 176 (14) 204 (17) 0.14
Hysterectomy, n (% yes) 1000 (41) 500 (40) 500 (40) Matched
Dietary factors
Alcohol, g/day c 0.9 (6.5) 1.0 (7.0) 0.6 (6.2) 0.02
Percent calories from carbohydrates c 52.2 (13.4) 52.8 (9.4) 51.2 (10.0) <0.01
Percent calories from protein c 16.8 (4.2) 16.9 (4.2) 16.8 (4.2) 0.63
Total energy, Kcal/day c 1506.4 (728.3) 1531.3 (702.4) 1482.2 (752.6) 0.84
Fish, servings/day b 0.3 (0.2) 0.3 (0.2) 0.2 (0.2) 0.28
Dairy products, servings/day b 1.9 (1.5) 1.9 (1.4) 1.9 (1.5) 0.53
Butter, teaspoons/day b 0.2 (0.5) 0.2 (0.5) 0.3 (0.6) <0.01
Margarine, teaspoons/day b 0.2 (0.5) 0.2 (0.5) 0.2 (0.5) 0.41
Olive/Canola oil, teaspoons/day b 0.1 (0.2) 0.1 (0.2) 0.1 (0.3) 0.57
Other vegetable oils, teaspoons/day b 0.1 (0.2) 0.0 (0.1) 0.1 (0.2) 0.28
Red meat, servings/day b 0.6 (0.5) 0.6 (0.5) 0.7 (0.6) <0.01
Carbohydrates, g/day b 202.5 (76.1) 204.2 (72.3) 200.8 (79.7) 0.27
a p values were derived using paired t test (continuous and normally distributed variables), Wilcoxon signed
rank test (continuous non-normally distributed variables), or McNemar test (categorical variables). b The mean
(SD) of normally distributed continuous variables. c The median (IQR) of continuous non-normally distributed
variables. d Medications included anticoagulant, anti-diabetic, and lipid lowering medications. Abbreviations: BMI
(body mass index), CHD (coronary heart disease), IQR (interquartile range), MET-h (metabolic equivalent-hours),
SD (standard deviation).
3.1. Associations between Increased Plasma PL-FA and CHD Risk
To examine the relationships between plasma PL-FA and CHD risk, we calculated the ORs (95% CIs)
of CHD in association with 1 moL % increase in plasma PL-FA (Table 3). In the adjusted multivariable
model, we observed higher CHD risk for increased plasma total PL SFA (OR = 1.20 (1.10–1.30)) and
long-chain SFA (OR = 1.18 (1.09–1.28)), but not for very-long-chain SFA (OR = 1.00 (0.77–1.30)). We also
observed a lower CHD risk associated with plasma PL PUFA n-3 (OR = 0.93 (0.88–0.99)). However,
no significant associations were observed for plasma PL MUFA, PUFA n-6, and TFA. The associations
between individual plasma PL-FA and CHD have been published elsewhere [15].
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Table 3. Multivariable adjusted associations (1 moL %) between plasma phospholipid fatty acids and
CHD risk in the matched case-control study (N = 2428).
Plasma Phospholipid Fatty Acids Mean (SD) Model 1
a Model 2 b
moL % OR (95% CIs) OR (95% CIs) OR (99% CIs)
SFA 46.09 (1.29) 1.19 (1.11, 1.28) 1.20 (1.10, 1.30) 1.20 (1.08, 1.34)
Long-chain SFA c 44.74 (1.37) 1.17 (1.09, 1.25) 1.18 (1.09, 1.28) 1.18 (1.07, 1.31)
Very-long-chain SFA d 1.35 (0.46) 1.00 (0.80, 1.26) 1.00 (0.77, 1.30) 1.00 (0.71, 1.41)
MUFA 11.77 (1.64) 0.96 (0.91, 1.01) 0.98 (0.93, 1.04) 0.98 (0.91, 1.06)
PUFA n-3 5.14 (1.58) 0.89 (0.84, 0.94) 0.93 (0.88, 0.99) 0.93 (0.86, 1.01)
PUFA n-6 36.31 (2.46) 1.03 (0.99, 1.06) 1.00 (0.96, 1.03) 1.00 (0.95, 1.05)
TFA 0.69 (0.34) 1.06 (0.84, 1.33) 1.01 (0.78, 1.31) 1.01 (0.72, 1.42)
a Model 1 adjusted for matching factors (age, race/ethnicity, enrollment date, and hysterectomy status). b Model 2
additionally adjusted for income, lifestyle factors (physical activity and smoking), CHD risk factors (family history of
myocardial infarction/diabetes, postmenopausal hormone use, and self-reported hypertension/diabetes), and dietary
factors (percent calories from protein/carbohydrates and total energy intake). c Long-chain SFA included lauric acid
(12:0), myristic acid (14:0), pentadecylic acid (15:0), palmitic acid (16:0), and stearic acid (18:0). d Very-long-chain
SFA included arachidic acid (20:0), behenic acid (22:0), and lignoceric acid (24:0). Abbreviations: CHD (coronary
heart disease), CIs (confidence intervals), MUFA (mono-unsaturated fatty acids), PUFA (polyunsaturated fatty
acids), OR (odds ratio), SD (standard deviation), SFA (saturated fatty acids), TFA (trans fatty acids).
3.2. Plasma PL-FA Substitutions
To further estimate the effect of substituting dietary PUFA n-6 or TFA with PUFA n-3 on CHD
risk, we calculated the ORs (95%CIs) of CHD risk from plasma PL-FA substitutions (Table 4). In the
initial models, lower CHD risk was observed when 1 moL % of plasma PL PUFA n-6 or TFA were
substituted with the same proportion of PUFA n-3. Although these associations were attenuated on
adjustment for covariates (model 2), results were still statistically significant at the 0.05 significance
level (OR = 0.90 (0.84–0.96) and 0.74 (0.56–0.99), respectively). However, in all models, substituting 1
moL % PL TFA with PUFA n-6 was not associated with CHD risk.
Table 4. Odds ratios (95% CIs) of CHD associated with 1 moL % substitutions between plasma
phospholipid fatty acid groups among participants in the matched case-control study (N = 2428).
Plasma Phospholipid Fatty Acids Model 1
a Model 2 b
OR (95% CIs) OR (95% CIs) OR (99% CIs)
PUFA n-6↓ PUFA n-3 ↑ (1 moL %) 0.85 (0.80, 0.90) 0.90 (0.84, 0.96) 0.90 (0.83, 0.98)
TFA↓ PUFA n-3 ↑ (1 moL %) 0.72 (0.55, 0.94) 0.74 (0.56, 0.99) 0.74 (0.51, 1.09)
TFA↓ PUFA n-6 ↑ (1 moL %) 0.84 (0.64, 1.11) 0.82 (0.61, 1.11) 0.82 (0.56, 1.22)
a Model 1 adjusted for matching factors (age, race/ethnicity, enrollment date, and hysterectomy status). b Model 2
additionally adjusted for income, lifestyle factors (physical activity and smoking), CHD risk factors (family history of
myocardial infarction/diabetes, postmenopausal hormone use, and self-reported hypertension/diabetes), and dietary
factors (percent calories from protein/carbohydrates and total energy intake). Abbreviations: CHD (coronary heart
disease), CIs (confidence intervals), PUFA (polyunsaturated fatty acids), OR (odds ratio), TFA (trans fatty acids).
3.3. Correlations between Plasma PL-FA and Select Food Groups
Correlations between food groups and plasma PL-FA levels have the potential to provide
information regarding food sources that may influence plasma PL-FA concentrations (Appendix C).
The strongest correlations that we found were in the PUFA n-3 group: fish and olive/canola oil intakes
were positively correlated with plasma PL PUFA n-3 (r = 0.34 and 0.12, respectively; p < 0.0001).
We also observed a positive correlation between alcohol intake and plasma PL long-chain SFA (r = 0.13;
p < 0.0001). Margarine and red meat intakes were positively correlated with plasma PL PUFA n-6 and
TFA (r ranges between 0.11 to 0.15; p < 0.0001).
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3.4. Sensitivity Analyses
In the sensitivity analysis of comparing difference regression models, our results were consistent
across models thus supporting the robustness of findings (Appendix D). When examining the association
between plasma PL-FA and CHD while adjusting for different anthropometric measures, we found
very similar results when adjusting for BMI, waist circumference, waist-to-hip ratio, or a three-year BMI
change (Appendix E). In the substitution analysis stratified by physical activity levels, we classified
participants into two groups: physically active (those with physical activity levels above the median,
9.5 MET-h/week) and physically inactive (those with physical activity levels ≤ 9.5 MET-h/week). As the
point estimates varied to a small extent between the physically active and inactive, physical activity is
less likely to be an effect modifier than a confounder (Appendix F). When comparing the association
and substitution analyses using complete cases versus multiple imputation, we observed very similar
results, thus suggesting the validity of the multiple imputation approach (Appendices G and H).
4. Discussion
This prospective matched case-control study nested in the WHI-OS assessed the association of
plasma PL-FA profile with CHD risk among 2428 postmenopausal women. In the adjusted analysis,
we found that higher PL SFA, especially long-chain SFA, were associated with increased CHD risk,
while higher PL PUFA n-3 were associated with lower CHD risk. No significant associations were
found for PL very-long-chain SFA, MUFA, PUFA n-6 and TFA. In the substitution analysis, we found
that substituting 1 moL % of plasma PL PUFA n-6 or TFA with the same proportion of PUFA n-3 were
associated with lower CHD risk.
4.1. Plasma PL SFA Profiles and CHD Risk
Individual SFA have diverse biological functions determined by the chain length [33]. For example,
the effect of raising LDL-C decreases as the chain length increases [33]. Long-chain SFA, especially palmitic
(16:0) and stearic (18:0) acids, are the primary dietary FA. Within the human body, long-chain SFA are a
major component of cell membranes, and endogenous synthesis contributes a significant portion of SFA
in the circulation with palmitic and stearic acids being the primary product [34]. Accumulating evidence
has supported the relationship of the aforementioned long-chain FA metabolism with potential CHD
risk [33]. The modest positive associations of total and long-chain PL SFA with CHD risk from our study
were consistent with some [26,35], but not all [36,37], cohort studies that have assessed either total or
individual SFA. The discordance may come from differences in age distributions, sources of blood SFA,
and specific SFA included in analyses.
We did not observe significant associations between very-long-chain plasma PL SFA and CHD risk,
which differs from a few recent population-based studies showing blood concentrations of very-long-chain
SFA were associated with lower risk of cardiometabolic conditions, including CHD [38] and diabetes [39].
The mechanisms underlying these observations are not well established. Compared with long-chain
SFA, very-long-chain SFA have lower water solubility and oxidation susceptibility, and they are major
components of ceramides and sphingomyelins that affect liver homeostasis, myelin maintenance,
and anti-inflammatory response through ceramide synthase expression, therefore showing potential
beneficial effects on CHD [40,41]. The discrepancies between our results and other studies may be
explained by the following: (1) differences in study populations: participants in other studies were
younger and had lower BMI, and research has shown that the association of very-long-chain SFA with
lower cardiometabolic risks appeared strongest in participants with normal BMI [39]; and (2) different
sources of SFA: most beneficial effects were identified from circulating very-long-chain SFA, while no
significant results were found from plasma PL or erythrocyte membranes.
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4.2. Plasma PL-FA Substitution in Groups
We observed a lower risk of CHD when substituting plasma PL PUFA n-6 with n-3. The beneficial
effects of PUFA n-3 on CHD have been reported in previous studies [12,14,15]. PUFA n-3 have been
shown to lower plasma triglyceride levels, to have anti-thrombotic and anti-arrhythmic properties,
to reduce macrophage infiltration into the vessel wall, and to reduce the proatherogenic secretion of
growth factors and cytokines by monocytes [42].
Although dietary TFA have been shown to increase CHD risk [43], we only observed a significant
change in CHD risk when substituting PL TFA with PUFA n-3, while no significant result was observed
when TFA were substituted with PUFA n-6. This discrepancy may be explained by the limitation in the
gas chromatography methodology we used to measure plasma PL-FA, which did not distinguish TFA
isomers elaidic acid (18:1 n-9 t) and vaccenic acid (18:1 n-11 t) [15]. It has been suggested that 18:1 n-11 t,
as the predominant TFA in dairy products, may have a weaker association with CHD compared with
other TFA resulting from partial hydrogenated vegetable oils, mainly 18:1 n-9 t [44]. Another possibility
is that the relatively small proportion of PL TFA, reflecting the dietary characteristics of the cohort of
older women, lead to a lack of power to detect an association.
The substitution analysis between different plasma PL-FA may be more informative than the
measured plasma PL-FA profiles themselves when examining the association of one type of plasma
PL-FA with CHD. The plasma PL-FA were measured in moL % with a summation of 100% for all
PL-FA, and 1 moL % increase in one type of plasma PL-FA is accompanied by reciprocal decrease
in 1 moL % for another. The plasma PL-FA substitution analysis is also more informative than the
substitution analysis of dietary FA and CHD risk, given that there is a lack of accuracy for each type of
dietary fat using any diet assessment method [45].
4.3. Potential Food Sources of Plasma PL-FA and Dietary Recommendations
The Spearman correlations we observed between plasma PL-FA and selected food groups were
moderate; however, they were consistent and comparable to previous evidence from other observational
studies using food frequency questionnaire as dietary measurement [18,46]. In short-term dietary
intervention trials and observational studies using multiple dietary measurements, the correlations
were stronger, therefore showing the measurement error in food frequency questionnaire might be a
cause of our moderate correlations [47,48].
The strongest correlation that we found was between plasma PL PUFA n-3 and fish intake. This result
is consistent with both observational study and dietary intervention trials [18,46], showing fatty fish
and fish oils are the predominant sources of PUFA n-3. We found a positive correlation between
plasma PL long-chain SFA and alcohol intake. This may be because alcohol can increase the activity of
acetyl-CoA carboxylase and FA synthase—the key enzymes in SFA 16:0 synthesis [49]. Our analysis
also showed that margarine and red meat intake was positively associated with plasma PL TFA levels.
Because humans do not synthesize TFA, diet contributes to the occurrence of these FA isomers in the
plasma. TFA can be found naturally from ruminant-animal meat (mainly 18:1 n-7 t), dairy fat (mainly
18:1 n-11 t), and unnaturally from industrially hydrogenated vegetable oils (mainly 18:1 n-9 t), such as
margarine [50].
Our findings are consistent with the recommendation made in the Scientific Report of the
2015 Dietary Guidelines Advisory Committee on food sources of nutrients among U.S. adults [51].
Foods associated with an increase of plasma PL long-chain SFA and TFA (including alcohol, red meat,
and margarine) should be limited. Dietary PUFA n-3, which can be found in fatty fish and canola
oil, should be recommended. However, caution is required when attempting to apply dietary
recommendations extrapolated from plasma levels of nutrients, which are only modestly correlated
with dietary intake.
There are several strengths of this study compared with previous ones. The matched case-control
design nested in a prospective cohort study allowed us to assess exposure in cases before the diagnosis
of CHD and select controls based on incidence density sampling, thus addressing the temporality
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between exposure and disease onset. In addition, our study is novel due to the focus on the association
of theoretical plasma PL-FA substitutions on CHD risk, which reflect in vivo FA metabolism as well as
dietary changes with less measurement error. However, our study had several limitations. We did not
detect all plasma PL-FA (such as short- and medium-chain SFA with carbons less than 12 and isomers
of TFA), thus limiting our analyses to a selective set of FA. However, these unmeasured FA are present
in very small amounts. Additional limitations include: (1) confounding bias due to unmeasured CHD
risk factors, such as blood lipids; and (2) limited evidence when extrapolating plasma PL-FA findings
to dietary changes.
5. Conclusions
This plasma PL-FA analysis suggests that long-chain SFA may be associated with increased risk of
CHD, and substituting PUFA n-6 or TFA with PUFA n-3 may be associated with lower risk of CHD.
Further work is needed on distinguishing the specific dietary factors that influence plasma PL-FA
levels within the context of the other covariates that may likewise impact outcomes.
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Appendix A
Table A1. Relationship of plasma phospholipid fatty acids a and socio-demographic, lifestyle, and CHD risk factors in the matched case-control study of the Women’s
Health Initiative Observational Study (1994–2005) (N = 2428).
SFA MUFA PUFA n-3 PUFA n-6 TFA
T1 T2 T3 p b T1 T2 T3 p b T1 T2 T3 p b T1 T2 T3 p b T1 T2 T3 p b
Median, moL % 44.8 46.0 47.3 10.4 11.6 13.3 3.9 4.9 6.5 34.0 36.5 38.5 0.4 0.6 1.0
Socio-demographics
Age, y c 67.8 68.1 67.5 0.34 67.4 68.1 67.9 0.16 67.4 67.7 68.3 <0.01 68.0 68.0 67.4 0.09 67.6 68.0 67.8 0.64
White, % 92 89 88 0.41 86 91 92 <0.01 93 89 86 <0.01 89 88 91 0.04 87 91 90 0.02
Income, % 0.94 0.24 <0.01 <0.01 <0.01
<$20,000 19 18 18 17 20 18 23 18 14 16 19 20 15 16 25
$20,000–$74,999 63 63 64 65 63 62 66 65 59 59 66 65 62 66 62
>$75,000 18 18 18 18 17 20 11 17 27 25 16 14 23 18 14
Lifestyle factors
PA, MET-h/week d 10.5 8.3 9.8 <0.01 8.6 9.5 10.5 <0.01 7.5 9.0 11.3 <0.01 11.1 9.0 7.8 <0.01 11.3 9.5 7.5 <0.01
BMI, kg/m2 d 25.2 26.2 27.8 <0.01 27.0 26.7 25.3 <0.01 27.1 26.5 25.8 <0.01 26.1 26.6 26.5 <0.01 26.0 26.6 26.6 <0.01
Smoking, % 0.24 0.06 <0.01 0.04 <0.01
Never 54 49 49 54 51 47 51 51 51 47 50 54 46 52 54
Past 40 43 44 40 43 45 39 43 46 46 43 39 46 423 39
Current 6 8 6 6 7 8 11 6 3 6 7 7 8 5 7
CHD risk factors
Family history, % yes
MI 57 56 58 0.75 59 53 55 0.37 56 59 56 0.41 58 56 57 0.75 57 57 57 0.93
Diabetes 31 32 38 0.01 36 31 33 0.24 35 36 30 0.03 33 36 34 0.30 33 38 13 0.02
Hormone usage 0.10 0.33 0.02 0.16 <0.01
Current E + P 14 13 17 13 16 15 13 14 17 17 13 14 17 14 13
Current E alone 20 23 24 23 25 21 20 25 23 23 24 21 25 25 18
Past Users 17 15 14 16 15 17 17 16 13 14 15 18 15 15 16
Never Used 49 48 45 49 45 48 50 45 47 46 48 47 44 45 52
Hypertension <0.01 <0.01 0.85 0.90 0.01
Never 67 54 55 55 57 63 59 57 57 58 58 59 53 59 62
Untreated 8 11 10 9 10 11 10 10 10 11 9 10 10 10 9
Treated 25 36 35 36 34 27 31 33 33 32 33 32 37 31 29
Diabetes, % 6 7 10 0.01 11 8 5 <0.01 10 8 6 0.01 6 8 10 0.01 8 9 7 0.62
Hysterectomy, % 39 41 43 0.19 43 42 38 0.13 42 43 39 0.28 39 41 43 0.25 40 45 38 0.01
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Dietary Factors
Alc, g/d d 0.5 1.0 1.0 0.02 0.5 1.0 1.2 <0.01 0.4 1.0 1.0 <0.01 1.1 1.0 0.2 <0.01 1.9 0.9 0.1 <0.01
Carb % cal d 52.3 51.2 52.6 0.55 50.9 52.0 53.4 <0.01 50.0 52.0 55.0 <0.01 54.7 52.3 49.7 <0.01 52.4 52.1 52.1 0.96
Protein % cal d 16.7 16.6 17.0 0.06 16.9 16.7 16.6 0.10 16.3 16.8 17.2 <0.01 17.2 16.6 16.5 <0.01 17.0 17.0 16.3 <0.01
Energy, kcal/d d 1481 1500 1541 0.03 1499 1495 1518 0.72 1558 1535 1426 <0.01 1524 1471 1533 0.15 1483 1542 1501 0.52
a Tertiles of plasma phospholipid fatty acids (moL %) b p trend: Test for linear trends were conducted by treating the median value for each quartile of fatty acids as a continuous
variable. c The mean (SD) of continuous variables. d The median (IQR) of continuous variables. Abbreviations: Alc (alcohol), BMI (body mass index). Cal (calories), Carb (carbohydrates),
CHD (coronary heart disease), E (Estrogen), MI (myocardial infarction), MET-h (metabolic equivalent-hours), MUFA (mono-unsaturated fatty acids), P (Progesterone), PA (physical
activity), PUFA (poly-unsaturated fatty acids), SFA (saturated fatty acids), TFA (trans fatty acids), SD (standard deviation), IQR (interquartile range).
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Figure A1. Hypothesized causal diagram for the matched case-control study. C1 includes age, 
race/ethnicity, life style factor (BMI, physical activity, and smoking), CHD risk factors (family history 
of myocardial infarction/diabetes/stroke, medication use, postmenopausal hormone use, self-
reported hypertension/diabetes/hypercholesterolemia, and hysterectomy status), and dietary factors 
(alcohol, percent calories from protein/carbohydrates, and total energy intake). C2 additionally 
included region, education, and income. A box around a node represents conditioning on that node. 
Abbreviations: BMI (body mass index), CHD (coronary heart disease), PL-FA (plasma phospholipid 
fatty acid). 
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myocardial infarction/diabetes/stroke, medication use, postmenopausal hormone use, self-reported
hypertension/diabetes/hypercholesterolemia, and hysterectomy status), and dietary factors (alcohol,
percent calories from protein/carbohydrates, and total energy intake). C2 additionally included region,
education, and income. A box around a node represents conditioning on that node. Abbreviations:
BMI (body mass index), CHD (coronary heart disease), PL-FA (plasma phospholipid fatty acid).
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Figure A2. The adjusted Spearman correlations a between plasma phospholipid fatty acids and select 
food groups. (A) Correlations between selected food groups and plasma PL long-chain SFA (B) 
Correlations between selected food groups and plasma PL PUFA n-3 (C) Correlations between 
selected food groups and plasma PL PUFA n-6 (D) Correlations between selected food groups and 
plasma PL TFA. a Correlations were adjusted for matching factors (age, race/ethnicity, enrollment 
date, and hysterectomy status), income, lifestyle factors (physical activity and smoking), and CHD 
risk factors (family history of myocardial infarction/diabetes, postmenopausal hormone use, and self-
reported hypertension/diabetes). Solid line—reference line of 0 Spearman correlations. Dashed line—
Spearman correlations among controls. * Significant Spearman correlations with p value < 0.0001. 
Abbreviations: CHD (coronary heart disease), PL (phospholipid), PUFA (polyunsaturated fatty 
acids), SFA (saturated fatty acids), TFA (trans fatty acids).
Figure A2. The adjusted Spearman correlations a between plasma phospholipid fatty acids and
select food groups. (A) Correlations between selected food groups and plasma PL long-chain SFA
(B) Correlations between selected food groups and plasma PL PUFA n-3 (C) Correlations between
selected food groups and plasma PL PUFA n-6 (D) Correlations between selected food groups and
plasma PL TFA. a Correlations were adjusted for matching factors (age, race/ethnicity, enrollment date,
and hysterectomy status), income, lifestyle factors (physical activity and smoking), and CHD risk factors
(family history of myocardial infarction/diabetes, postmenopausal hormone use, and self-reported
hypertension/diabetes). Solid line—reference line of 0 Spearman correlations. Dashed line—Spearman
correlations among controls. * Significant Spearman correlations with p value < 0.0001. Abbreviations:
CHD (coronary heart disease), PL (phospholipid), PUFA (polyunsaturated fatty acids), SFA (saturated
fatty acids), TFA (trans fatty acids).
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Appendix D
Table A2. Associations between plasma phospholipid fatty acids (1 moL %) and CHD risk adjusting for different confounders in the matched case-control study (N = 2428).
Plasma Phospholipid Fatty Acids Crude Model a Fully Adjusted Model b Parsimonious Model c Adjusted Model from a Prior Study [15] d
SFA 1.19 (1.11, 1.28) 1.23 (1.13, 1.34) 1.20 (1.10, 1.30) 1.20 (1.08, 1.32)
Long-chain SFA 1.17 (1.09, 1.25) 1.21 (1.12, 1.32) 1.18 (1.09, 1.28) NR
Very-long-chain SFA 1.00 (0.80, 1.26) 1.00 (0.76, 1.30) 1.00 (0.77, 1.30) NR
MUFA 0.96 (0.91, 1.01) 0.99 (0.93, 1.05) 0.98 (0.93, 1.04) 0.97 (0.91, 1.04)
PUFA n-3 0.89 (0.84, 0.94) 0.94 (0.88, 0.99) 0.93 (0.88, 0.99) 0.89 (0.83, 0.97)
PUFA n-6 1.03 (0.99, 1.06) 0.98 (0.95, 1.03) 1.00 (0.96, 1.03) 1.02 (0.97, 1.07)
TFA 1.06 (0.84, 1.33) 0.97 (0.74, 1.27) 1.01 (0.78, 1.31) 1.00 (0.81, 1.24)
a Crude model adjusted for matching factors (age, race/ethnicity, enrollment date, and hysterectomy status). b Fully adjusted model additionally included socio-demographic variables
(region, education, and income), lifestyle factors (physical activity, BMI, smoking), and CHD risk factors (family history of MI/diabetes/stroke, medication use, postmenopausal hormone use,
and self-reported hypertension/diabetes/hypercholesterolemia), and dietary factors (dietary alcohol intake, percent calories from protein/carbohydrates, and total energy intake). c Parsimonious
model included matching factors, income, lifestyle factors (physical activity and smoking), CHD risk factors (family history of myocardial infarction/diabetes, postmenopausal hormone use,
and self-reported hypertension/diabetes), and dietary factors (percent calories from protein/carbohydrates, and total energy intake). d Adjusted model from the prior study included matching
factors, education, BMI, lifestyle factors (physical activity, BMI, smoking), CHD risk factors (systolic blood pressure, family history of cardiovascular disease/stroke/MI/diabetes, medication use,
and postmenopausal hormone use), and dietary factors (carbohydrate, protein, and alcohol intake). Abbreviations: BMI (body mass index), CHD (coronary heart disease), MI (myocardial
infarction), MUFA (monounsaturated fatty acids), NR (not reported), PUFA (polyunsaturated fatty acids), SFA (saturated fatty acids), TFA (trans fatty acids).
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Table A3. Associations (1 moL %) between plasma phospholipid fatty acids and CHD risk when adjusting for different anthropometric measures in the matched
case-control study (N = 2428).
Plasma Phospholipid
Fatty Acids
BMI Adjusted Model a
OR (95% CIs)
Waist Circumference Adjusted Model a
OR (95% CIs)
Waist: Hip Adjusted Model a
OR (95% CIs)
BMI Change Adjusted Model a,b
OR (95% CIs)
SFA 1.20 (1.10, 1.30) 1.17 (1.08, 1.28) 1.17 (1.08, 1.28) 1.26 (1.13, 1.39)
Long-chain SFA 1.18 (1.09, 1.28) 1.16 (1.07, 1.26) 1.16 (1.07, 1.26) 1.23 (1.12, 1.36)
Very-long-chain SFA 1.00 (0.77, 1.30) 1.01 (0.78, 1.32) 0.99 (0.76, 1.29) 1.04 (0.75, 1.44)
MUFA 0.99 (0.93, 1.05) 0.99 (0.94, 1.05) 1.00 (0.94, 1.05) 0.97 (0.90, 1.04)
PUFA n-3 0.93 (0.88, 0.99) 0.93 (0.88, 0.99) 0.94 (0.88, 1.00) 0.93 (0.87, 1.00)
PUFA n-6 1.00 (0.96, 1.03) 1.00 (0.96, 1.04) 0.99 (0.96, 1.03) 0.99 (0.95, 1.04)
TFA 1.00 (0.78, 1.30) 1.04 (0.80, 1.35) 1.00 (0.77, 1.31) 1.01 (0.74, 1.39)
a Multivariable model included matching factors (age, race/ethnicity, enrollment date, and hysterectomy status), income), lifestyle factors (physical activity and smoking), CHD risk factors
(family history of myocardial infarction /diabetes, postmenopausal hormone use, and self-reported hypertension /diabetes), and dietary factors (percent calories from protein/carbohydrates,
and total energy intake). b BMI change indicated the difference between two BMI measures, one at baseline and one at year 3. Abbreviations: BMI (body mass index), CHD (coronary heart
disease), CIs (confidence intervals), MUFA (mono-unsaturated fatty acids), PUFA (polyunsaturated fatty acids), OR (odds ratio), SFA (saturated fatty acids), TFA (trans fatty acids).
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Appendix F
Table A4. Odds ratios a (95% CIs) of CHD associated with 1 moL % substitutions between plasma
phospholipid fatty acid groups stratified by physical activity levels in the matched case-control study
(N = 2428).
Plasma Phospholipid Fatty Acids Overall Physically Active Physically Inactive
PUFA n-6 ↓ PUFA n-3 ↑ (1 moL %) 0.90 (0.84, 0.96) 0.95 (0.84, 1.06) 0.88 (0.76, 1.02)
TFA ↓ PUFA n-3 ↑ (1 moL %) 0.74 (0.56, 0.99) 0.88 (0.50, 1.54) 1.04 (0.60, 1.82)
TFA ↓ PUFA n-6↑ (1 moL %) 0.82 (0.61, 1.11) 0.92 (0.52, 1.65) 1.19 (0.67, 2.11)
a Multivariable model adjusted for matching factors (age, race/ethnicity, enrollment date, and hysterectomy
status), income, lifestyle factors (physical activity and smoking), CHD risk factors (family history of myocardial
infarction/diabetes, postmenopausal hormone use, and self-reported hypertension/diabetes), and dietary factors
(percent calories from protein/carbohydrates and total energy intake). Abbreviations: CHD (coronary heart disease),
CIs (confidence intervals), PUFA (polyunsaturated fatty acids), TFA (trans fatty acids).
Appendix G
Table A5. Multivariable adjusted associations a (1 moL %) between plasma phospholipid fatty acids
and CHD risk among participants with complete information versus using multiple imputation in the
matched case-control study.
Plasma Phospholipid Fatty Acids Complete Analysis (N = 2181) Multiple Imputation (N = 2428)
OR (95% CIs) OR (95% CIs)
SFA 1.21 (1.08, 1.35) 1.20 (1.10, 1.30)
Long-chain SFA b 1.19 (1.07, 1.33) 1.18 (1.09, 1.28)
Very-long-chain SFA c 0.99 (0.70, 1.41) 1.00 (0.77, 1.30)
MUFA 0.98 (0.91, 1.06) 0.98 (0.93, 1.04)
PUFA n-3 0.93 (0.86, 1.01) 0.93 (0.88, 0.99)
PUFA n-6 1.00 (0.95, 1.05) 1.00 (0.96, 1.03)
TFA 0.97 (0.69, 1.38) 1.01 (0.78, 1.31)
a Multivariable model adjusted for matching factors (age, race/ethnicity, enrollment date, and hysterectomy
status), income, lifestyle factors (physical activity and smoking), CHD risk factors (family history of myocardial
infarction/diabetes, postmenopausal hormone use, and self-reported hypertension/diabetes), and dietary factors
(percent calories from protein/carbohydrates and total energy intake). b Long-chain SFA included lauric acid (12:0),
myristic acid (14:0), pentadecylic acid (15:0), palmitic acid (16:0), and stearic acid (18:0). c Very-long-chain SFA
included arachidic acid (20:0), behenic acid (22:0), and lignoceric acid (24:0). Abbreviations: CHD (coronary heart
disease), CIs (confidence intervals), MUFA (mono-unsaturated fatty acids), PUFA (polyunsaturated fatty acids),
OR (odds ratio), SFA (saturated fatty acids), TFA (trans fatty acids).
Appendix H
Table A6. Odds ratios a (95% CIs) of CHD associated with 1 moL % substitutions between plasma
phospholipid fatty acid groups among participants with complete information versus using multiple
imputation in the matched case-control study.
Plasma Phospholipid Fatty Acids Complete Analysis (N = 2181) Multiple Imputation (N = 2428)
OR (95% CIs) OR (95% CIs)
PUFA n-6 ↓ PUFA n-3 ↑ (1 moL %) 0.90 (0.85, 0.97) 0.90 (0.84, 0.96)
TFA ↓ PUFA n-3 ↑ (1 moL %) 0.75 (0.57, 1.00) 0.74 (0.56, 0.99)
TFA ↓ PUFA n-6↑ (1 moL %) 0.85 (0.62, 1.15) 0.82 (0.61, 1.11)
a Multivariable model adjusted for matching factors (age, race/ethnicity, enrollment date, and hysterectomy
status), income, lifestyle factors (physical activity and smoking), CHD risk factors (family history of myocardial
infarction/diabetes, postmenopausal hormone use, and self-reported hypertension/diabetes), and dietary factors
(percent calories from protein/carbohydrates and total energy intake).Abbreviations: CHD (coronary heart disease),
CIs (confidence intervals), PUFA (polyunsaturated fatty acids), OR (odds ratio), TFA (trans fatty acids).
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